...with an exercise price of $9.40 per share. Investors included S.A.C. Capital; S.A.C. HealthCo Fund; Narragansett Asset Management...

...share, which may be adjusted to $7.95 per share based on future issuances. Investors included Narragansett Asset Management...

...the ALT-711 advanced glycosylation end-product (A.G.E.) compound in cardiovascular disease. The investors, including S.A.C. Capital, Narragansett Asset Management...